The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

A proposed bill in the Colorado General Assembly bill is aiming to regulate the ingredients used for transparency and safety.

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

The FDA has issued warnings to 30 telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a year-long campaign to ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.

FORT MYERS, Fla. — Noah Song’s dream of pitching in the major leagues has never been closer. The 2019 Naval Academy product had a chance to skip the minor leagues altogether when the Philadelphia ...

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will no longer advertise compounded GLP-1 drugs, the company announced Monday. Instead, ...

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.